Author

Andreas von Deimling

Primary ORCID profile (0000-0002-5863-540X · 8 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Andreas von DeimlingiD8 papers · German Cancer Research Center

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Andrea NistiD· 1 shared Constanze Schneider· 1 shared Daniel SpeideliD· 1 shared Florian Rothweiler· 1 shared Jindrich CinatliD· 1 shared Marco Mernberger· 1 shared Martin MichaelisiD· 1 shared Tamara Rothenburger· 1 shared

Activity by Year

2018-2018 · peak 1/yr

Co-Author Collaboration Network

9 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Andrea NistORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

TP53 mutations and drug sensitivity in acute myeloid leukaemia cells with acquired MDM2 inhibitor resistance

Martin Michaelis, Constanze Schneider, Florian Rothweiler, Tamara Rothenburger, Marco Mernberger, Andrea Nist, Andreas von Deimling, Daniel Speidel, Thorsten Stiewe, Jindrich Cinatl

This study establishes MDM2 inhibitor-resistant AML sub-lines and finds that resistance arises from pre-existing TP53 mutations or de novo mutations, with variable drug sensitivity despite loss of p53 function.

bioRxiv · Aug 30, 2018 · PreprintPharmacology & Toxicology